Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference

Strategic healthcare assets: A diversified set of investments that Raifeld said is currently valued at over $600 million , with recent momentum driven in part by clinical progress at Armata.Innoviva Specialty Therapeutics (IST): A commercial-stage critical care infectious disease platform. Raifeld said IST delivered almost $120 million in U.S. sales last year and that the company expects at least $150 million this year. He also pointed to a “best quarter ever” with $34 million in U.S. sales, describing it a ...